Cargando…

94. Pooled analysis of nirsevimab resistance through 150 days post dose in preterm and term infants

BACKGROUND: Respiratory syncytial virus (RSV) is the major cause of lower respiratory tract infection (LRTI) and hospitalization in infants. In two global pivotal placebo-controlled studies, nirsevimab, a monoclonal antibody to the RSV prefusion (F) protein with extended half-life, reduced medically...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abram, Michael E, Ahani, Bahar, Tabor, David E, Fernandes, Fiona, Wilkins, Deidre, Aksyuk, Anastasia A, Tuffy, Kevin M, Ji, Hong, Blaze, Christine, Brady, Tyler, Griffin, Pamela, Leach, Amanda, Villafana, Tonya L, Esser, Mark T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752125/ http://dx.doi.org/10.1093/ofid/ofac492.019

Ejemplares similares

2641. Nirsevimab binding-site conservation in RSV F protein between 2015 and 2022: The US OUTSMART-RSV surveillance study
por: Morehouse, Christopher A, et al.
Publicado: (2023)

Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials
por: Ahani, Bahar, et al.
Publicado: (2023)

Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants
por: Wilkins, Deidre, et al.
Publicado: (2023)

Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection
por: Brady, Tyler, et al.
Publicado: (2023)

1934. Nirsevimab is Associated with Higher and More Sustained RSV Neutralizing Antibody Responses Compared with Standard of Care Palivizumab: Observations from a 2:1 Randomized, Phase 2/3 Trial in Medically Vulnerable Children (MEDLEY)
por: Wilkins, Deidre, et al.
Publicado: (2023)

Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease
por: Domachowske, Joseph B, et al.
Publicado: (2023)

Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials
por: Simões, Eric A F, et al.
Publicado: (2023)

LB13. The Efficacy and Impact in Heathy Infants of Nirsevimab on Medically Attended RSV Lower Respiratory Tract Infection
por: Hammitt, Laura, et al.
Publicado: (2021)

Validation and performance of a multiplex serology assay to quantify antibody responses following SARS‐CoV‐2 infection or vaccination
por: Wilkins, Deidre, et al.
Publicado: (2022)

Inequalities in Health Impact of Alternative Reimbursement Pathways for Nirsevimab in the United States
por: Gomez, Gabriela B, et al.
Publicado: (2022)

901. MEDI8897 Prevents Serious RSV Disease in Healthy Preterm Infants
por: Pamela Griffin, Mary, et al.
Publicado: (2019)

Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants
por: Tuffy, Kevin M, et al.
Publicado: (2023)

Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants
por: Domachowske, Joseph B., et al.
Publicado: (2018)

Nirsevimab brings breakthrough in the prevention of respiratory syncytial virus infection in infants – Importance of design
por: Zhaori, Getu
Publicado: (2023)

89. The Impact of Nirsevimab on an RSV Season in All Infants: Data From The HARMONIE Study
por: Faust, Saul N, et al.
Publicado: (2023)

Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated
por: Maaske, Jill, et al.
Publicado: (2023)

The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: A systematic review and meta-analysis
por: Turalde-Mapili, Maria Wilma R., et al.
Publicado: (2023)

Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper
por: Esposito, Susanna, et al.
Publicado: (2021)

Global Molecular Epidemiology of Respiratory Syncytial Virus from the 2017−2018 INFORM-RSV Study
por: Tabor, David E., et al.
Publicado: (2020)

A Single Dose Monoclonal Antibody (mAb) Immunoprophylaxis Strategy to Prevent RSV Disease in All Infants: Results of the First in Infant Study with MEDI8897
por: Domachowske, Joseph B, et al.
Publicado: (2017)

Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults
por: Griffin, M. Pamela, et al.
Publicado: (2017)

The 150 most important questions in cancer research and clinical oncology series: questions 94–101: Edited by Cancer Communications
Publicado: (2018)

Overexpressing microRNA-150 attenuates hypoxia-induced human cardiomyocyte cell apoptosis by targeting glucose-regulated protein-94
por: Ma, Jian-Lin, et al.
Publicado: (2018)

Potential Impact of Nirsevimab on RSV Transmission and Medically Attended Lower Respiratory Tract Illness Caused by RSV: A Disease Transmission Model
por: Voirin, Nicolas, et al.
Publicado: (2021)

Characterization of human respiratory syncytial virus (RSV) isolated from HIV‐exposed‐uninfected and HIV‐unexposed infants in South Africa during 2015‐2017
por: Liu, Hui, et al.
Publicado: (2020)

Symphony No. 94 Surprise Symphony No. 94 Miracle/
por: Haydn, Joseph

Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
por: Jones, Jefferson M., et al.
Publicado: (2023)

www 94
Publicado: (2017)

Hadron '94
por: Collective
Publicado: (1994)

Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants
por: Roe, Tiffany L., et al.
Publicado: (2023)

Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model
por: Kieffer, Alexia, et al.
Publicado: (2022)

Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study
por: Shoukat, Affan, et al.
Publicado: (2023)

CPS94-RF # 14: Réunion du 18/10/94
por: Garoby, R
Publicado: (1994)

CPS94-RF #6 Réunion du 11/04/94
por: Arruat, Μ, et al.
Publicado: (1994)

CPS94-RF #1 Réunion du 25/01/94
por: Arruat, Μ, et al.
Publicado: (1994)

CPS94-RF #2: Réunion du 1/02/94
por: Armat, M, et al.
Publicado: (1994)

CPS94-RF #9: Réunion du 24/05/94
por: Garoby, R, et al.
Publicado: (1994)

CPS94-RF#13: Réunion du 16/09/94
por: Garoby, R
Publicado: (1994)

CPS94-RF #4 Réunion du 15/02/94
por: Garoby, R
Publicado: (1994)

CPS94-RF #5 Réunion du 14/03/94
por: Arruat, M, et al.
Publicado: (1994)

Cannot write session to /tmp/vufind_sessions/sess_mjngd18ln608g7944eq3j8b8cs